The Andhra Pradesh MedTech Zone (AMTZ) today launched the MedTech Hackathon 2026, “Hack Health: Innovate to Heal,” bringing together startups, innovators, clinicians, and industry leaders to rapidly develop technology driven solutions for pressing healthcare challenges. Scheduled from April 4 to April 7, 2026, the hackathon opened
Visakhapatnam, 22th December 2025 – Bio Valley Incubation Council, the Bioincubator arm of the Andhra Pradesh MedTech Zone (AMTZ), is emerging as a key engine powering India’s next generation of healthcare startups. By enabling innovators to move from laboratory research to market-ready solutions faster, safer
Second quarter revenue from operations grows 4% sequentially and 2% year-on-year to Rs. 911 Cr 1st half revenue from operations up 6% Syngene International Limited today announced financial results for the second quarter and half year of FY26. Quarterly Financial Highlights (All numbers are in Indian Rupees in Cr except margins) Q2 FY25 Q2 FY26 YoY Change (%) Revenue from Operations 891 911 2% Reported Revenue 908 926 2% Reported EBITDA 261 215 -18% Reported EBITDA margin (%) 28.8% 23.2% Reported PAT (before exceptional items) 106 67 -37% Reported PAT Margin (%) 11.7% 7.3% H1 FY26 Financial Highlights (All numbers are in Indian rupees in Crores except margins) H1 FY25 H1 FY26 YoY Change (%) Revenue from Operations 1,681 1,785 6% Reported Revenue 1,715 1,818 6% Reported EBITDA 449 439 -2% Reported EBITDA margin (%) 26.2% 24.1% Reported PAT (before exceptional items) 161* 154 -4% Reported PAT Margin (%) 9.4% 8.5% Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim. Commenting on the results, Peter Bains, Managing Director and CEO, Syngene International Limited, said, “Our Q2 performance was driven by underlying revenue growth from research
India’s leading vaccine innovator Bharat Biotech has announced the establishment of a Contract Research, Development, and Manufacturing Organization (CRDMO) division dedicated to cell and gene therapy, marking a strategic expansion into one of the most advanced frontiers in biomedical science. The new CRDMO arm will focus
The evolving biosimilar regulations in the United States are poised to create new growth opportunities for Indian pharmaceutical companies, with experts predicting a significant uptick in exports and partnerships in the biopharma segment. The U.S. Food and Drug Administration’s (FDA) streamlined approval pathway for biosimilars, along
Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies services Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully
The Indian Pharmaceutical Alliance (IPA) has announced the appointment of Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, as its new President. Dr. Patel will lead the industry body for the next two years, succeeding Samina Hamied, Executive Vice Chairperson of Cipla Ltd., who successfully
Ravishankar Gopalakrishnan, Group Chief Operating Officer & Wholetime Director, Medikabazaar penned down: India’s healthcare ecosystem is evolving rapidly, and with it comes an urgent need to modernise the medical logistics infrastructure that supports it. According to a report by Grand View Research, the healthcare supply chain
Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and nine months ended December 31st, 2024. Key Financial Highlights Q3 FY25 Highlights Revenue from operations at Rs. 52,691 mn, up 17% over last year. Research & Development (R&D) investments for the quarter stood
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crores Syngene International Limited today announced its third quarter financial results. Reported revenue from operations was up by 11% year-on-year to Rs. 944
